For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
12 - 12 mg per m² of body surface area (BSA)
From 12 To 12 mg per m² of body surface area (BSA) once every day for 3 day(s)
As single agent in ALL the suggested dose in adults is 12 mg/m² i.v. daily for 3 days.